Schmoll HJ, Lindner LH, Reichardt P, et al. - Researchers undertook this multicenter, randomized phase 2 clinical trial to ascertain the effectiveness of gemcitabine and pazopanib vs pazopanib alone in pretreated soft tissue sarcoma. Included patients were those with an Eastern Cooperative Oncology Group performance status score of 0 to 2, adequate organ function, measurable lesion, and progression following at least 1 prior therapy with anthracyclines and/or ifosfamide. These patients were randomly assigned to pazopanib with gemcitabine or without gemcitabine. Findings showed not only the tolerability of gemcitabine added to pazopanib, but also the effectiveness of this combination in affording a significantly higher progression-free survival rate at 12 weeks vs pazopanib alone in patients with pretreated soft tissue sarcoma. The clinical activity of the combination was suggested, but confirmation in a phase 3 trial in a more homogeneous population (eg, leiomyosarcoma) is advised.